Drug intelligence / Profile preview

Rabeprazole, Aspirin, and Clopidogrel Combination

Development stage: Unknown
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three medications sometimes used together in clinical practice, particularly for patients with cardiovascular conditions who also have gastrointestinal concerns. Rabeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production. Aspirin is an antiplatelet agent that helps prevent blood clots. Clopidogrel is also an antiplatelet medication that works through a different mechanism than aspirin.

Targets

P2Y12 (Purinergic P2Y12 receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Rabeprazole, Aspirin, and Clopidogrel Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabeprazole, Aspirin, and Clopidogrel Combination.

Explore the full profile